{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:08:48Z","timestamp":1794438528910,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,19]]},"abstract":"<jats:p>This study aimed to compare viral suppression (VS) between children, adolescents, and adults in the frame of transition to dolutegravir (DTG)-based antiretroviral therapy (ART) in the Cameroonian context. A comparative cross-sectional study was conducted from January 2021 through May 2022 amongst ART-experienced patients received at the Chantal BIYA International Reference Centre in Yaounde-Cameroon, for viral load (VL) monitoring. VS was defined as VL &lt; 1000 copies\/mL and viral undetectability as VL &lt; 50 copies\/mL. Chi-square and multivariate binary logistic regression models were used to identify factors associated with VS. Data were analyzed using SPSS v.20.0 (SPSS Inc., Chicago, Illinois), with <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05 considered significant. A total of 9034 patients (72.2% females) were enrolled. In all, there were 8585 (95.0%) adults, 227 (2.5%) adolescents, and 222 (2.5%) children; 1627 (18.0%) were on non-nucleoside reverse transcriptase-based, 290 (3.2%) on PI-based, and 7117 (78.8%) on DTG-based ART. Of those on DTG-based ART, only 82 (1.2%) were children, 138 (1.9%) adolescents, and 6897 (96.9%) adults. Median (interquartile range) duration on ART was 24 (12\u201372) months (24 months on Tenofovir + Lamivudine + Dolutegravir [TLD], 36 months on other first lines, and 84 months on protease inhibitors boosted with ritonavir-based regimens). Overall, VS was 89.8% (95% confidence interval: 89.2\u201390.5) and viral undetectability was 75.7% (95% confidence interval: 74.8\u201376.7). Based on ART regimen, VS on Non-nucleoside reverse transcriptase-based, protease inhibitors boosted with ritonavir-based, and DTG-based therapy was respectively 86.4%, 59.7%, and 91.8%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001. Based on ART duration, VS was respectively 51.7% (\u226424 months) versus 48.3% (\u226525 months), <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001. By gender, VS was 90.9% (5929) in females versus 87.0% (2183) in males, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001; by age-range, VS moved from 64.8% (144) in children, 74.4% (169) adolescents, to 90.8% (7799) adults, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001. Following multivariate analysis, VS was associated with adulthood, female gender, TLD regimens, and combination antiretroviral therapy duration &gt; 24 months (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05). In Cameroon, ART response indicates encouraging rates of VS (about 9\/10) and viral undetectability (about 3\/4), driven essentially by access to TLD based regimens. However, ART response was very poor in children, underscoring the need for scaling-up pediatric DTG-based regimens.<\/jats:p>","DOI":"10.1097\/md.0000000000033737","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:02:30Z","timestamp":1684450950000},"page":"e33737","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":31,"title":["Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics"],"prefix":"10.1097","volume":"102","author":[{"given":"Joseph","family":"Fokam","sequence":"first","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Faculty of Health Sciences, University of Buea, Buea, Cameroon"},{"name":"National HIV Drug Resistance Working Group, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-8661","authenticated-orcid":false,"given":"Alex Durand","family":"Nka","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"The University of Rome Tor Vergata, Rome, Italy"},{"name":"Evangelic University of Cameroon, Bandjoun, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore Yollande","family":"Mamgue Dzukam","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Faculty of Health Sciences, University of Buea, Buea, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Efakika Gabisa","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yagai","family":"Bouba","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"The University of Rome Tor Vergata, Rome, Italy"},{"name":"Central Technical Group, National AIDS Control Committee, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Carlos","family":"Tommo Tchouaket","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"School of Health Sciences, Catholic University of Central Africa, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude Christelle","family":"Ka\u2019e","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"The University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezechiel","family":"Ngoufack Jagni Semengue","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"The University of Rome Tor Vergata, Rome, Italy"},{"name":"Evangelic University of Cameroon, Bandjoun, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desire","family":"Takou","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Moudourou","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Fainguem","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"The University of Rome Tor Vergata, Rome, Italy"},{"name":"Evangelic University of Cameroon, Bandjoun, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Pabo","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Faculty of Sciences, University of Buea, Buea, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Audrey","family":"Nayang Mundo","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie Minelle","family":"Kengni Ngueko","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collins","family":"Ambe Chenwi","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Mvangan District Hospital, Mvangan, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junie","family":"Flore Yimga","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Krystel","family":"Nnomo Zam","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Simo Kamgaing","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Tangimpundu","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Kamgaing","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Esther","family":"Njom-Nlend","sequence":"additional","affiliation":[{"name":"Higher Institute of Medical Technology, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ndombo Koki","sequence":"additional","affiliation":[{"name":"Mother-Child Centre, Chantal BIYA Foundation, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kesseng","sequence":"additional","affiliation":[{"name":"Mother-Child Centre, Chantal BIYA Foundation, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzie","family":"Ndiang Tetang","sequence":"additional","affiliation":[{"name":"Essos Health Centre, National Social Welfare Centre, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Kembou","sequence":"additional","affiliation":[{"name":"World Health Organisation Afro, Country Office, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifanda","family":"Ebiama Lifanda","sequence":"additional","affiliation":[{"name":"Central Technical Group, National AIDS Control Committee, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouba","family":"Pamen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon"},{"name":"World Health Organisation Afro, Country Office, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ketchaji","sequence":"additional","affiliation":[{"name":"Division of Disease, Epidemic and Pandemic Control, Ministry of Public Health, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Saounde Temgoua","sequence":"additional","affiliation":[{"name":"Central Technical Group, National AIDS Control Committee, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge Clotaire","family":"Billong","sequence":"additional","affiliation":[{"name":"National HIV Drug Resistance Working Group, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon"},{"name":"Central Technical Group, National AIDS Control Committee, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Cecile","family":"Zoung-Kanyi Bissek","sequence":"additional","affiliation":[{"name":"National HIV Drug Resistance Working Group, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon"},{"name":"Division of Health Operational Research, Ministry of Public Health, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamsatou","family":"Hadja","sequence":"additional","affiliation":[{"name":"Central Technical Group, National AIDS Control Committee, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edie Gregory","family":"Halle","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Buea, Buea, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Colizzi","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"The University of Rome Tor Vergata, Rome, Italy"},{"name":"Evangelic University of Cameroon, Bandjoun, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo-Federico","family":"Perno","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Bambino Gesu Pediatric Hospital, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Martin","family":"Sosso","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ndjolo","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12981-019-0252-0","article-title":"Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of \u201ctest and treat\u201d.","volume":"16","author":"Fokam","year":"2019","journal-title":"AIDS Res Ther"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"e7702","DOI":"10.1371\/journal.pone.0007702","article-title":"Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV Preve Ameroon Cameroon.","volume":"4","author":"Aghokeng","year":"2009","journal-title":"PLoS One"},{"issue":"Suppl Suppl 8","key":"R13-20250504","first-page":"e25187","article-title":"Journal of the International AIDS society published by John Wiley & Sons Ltd on behalf of the International AIDS society. HIV Glasgow 2018, 28\u201331 October 2018, Glasgow, UK.","volume":"21","year":"2018","journal-title":"J Int AIDS Soc [Internet]"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/cit627","article-title":"Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in Sub-Saharan Africa and southeast Asia.","volume":"58","author":"Aghokeng","year":"2014","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"ofw233","DOI":"10.1093\/ofid\/ofw233","article-title":"Virologic failure and human immunodeficiency virus drug resistance Ameroon Cameroon with regard to the UNAIDS 90-90-90 treatment targets.","volume":"3","author":"Boull\u00e9","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eclinm.2018.06.005","article-title":"Nationwide estimates of viral load suppression and acquired HIV drug resistance in Cameroon.","volume":"1","author":"Tchouwa","year":"2018","journal-title":"EClinicalMedicine"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e72680","DOI":"10.1371\/journal.pone.0072680","article-title":"Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a Sentinel Ameroon Cameroon: low levels of resistance but poor programmatic performance.","volume":"8","author":"Billong","year":"2013","journal-title":"PloS One"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e11463","DOI":"10.1097\/MD.0000000000011463","article-title":"Treatment outcomes and HIV drug resistance of patients switching to second-line regimens after long-term first-line antiretroviral therapy.","volume":"97","author":"Cao","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/QAD.0000000000002936","article-title":"Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.","volume":"35","author":"Keene","year":"2021","journal-title":"AIDS Lond Engl"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2174\/157016212800792469","article-title":"Response to antiretroviral treatment after failure of NNRTI Plus NRTIs-based therapy. Data from the ARCA collaborative group.","volume":"10","author":"Seminari","year":"2012","journal-title":"Curr HIV Res"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/135965350801300707","article-title":"Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.","volume":"13","author":"Geretti","year":"2008","journal-title":"Antivir Ther"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2147\/IDR.S158341","article-title":"Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study.","volume":"11","author":"Cheng","year":"2018","journal-title":"Infect Drug Resist"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1468-1293.2008.00628.x","article-title":"Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.","volume":"9","author":"Charpentier","year":"2008","journal-title":"HIV Med"},{"key":"R25-20250504","first-page":"65","article-title":"Patterns of resistance development with integrase inhibitors in HIV.","volume":"4","author":"Mbisa","year":"2011","journal-title":"Infect Drug Resist"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications.","volume":"203","author":"Blanco","year":"2011","journal-title":"J Infect Dis"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.3389\/fmicb.2016.02165","article-title":"Different pathways leading to integrase inhibitors resistance.","volume":"7","author":"Thierry","year":"2017","journal-title":"Front Microbiol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/jac\/dkz021","article-title":"Resistance to integrase inhibitors: a national study in HIV-1-infected tIent-naive and -experienced patients.","volume":"74","author":"Marcelin","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12879-017-2428-3","article-title":"Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014-July 2015.","volume":"17","author":"Bulage","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"5","key":"R34-20250504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/QAI.0000000000001715","article-title":"Lack of virological suppression among young HIV-positive adults in Botswana.","volume":"78","author":"Novitsky","year":"2018","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"ofy200","DOI":"10.1093\/ofid\/ofy200","article-title":"Low case finding among men and poor viral load suppression among adolescents are impeding Namibia\u2019s ability to achieve UNAIDS 90-90-90 targets.","volume":"5","author":"Agolory","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/aid.2015.0296","article-title":"Younger age predicts failure to achieve viral suppression and virologic rebound among HIV-1-infected persons in serodiscordant partnerships.","volume":"32","author":"Mujugira","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"R37-20250504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3851\/IMP3020","article-title":"High level of virological suppression among HIV-infected adults receiving combination antiretroviral therapy in Addis Ababa, Ethiopia.","volume":"21","author":"Mekuria","year":"2016","journal-title":"Antivir Ther"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment.","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr Opin Virol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/jac\/dkx053","article-title":"Tolerability of integrase inhibitors in a real-life setting.","volume":"72","author":"Pe\u00f1afiel","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:04:27Z","timestamp":1746324267000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":24,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033737","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,19]]}}}